Meningitis: analysis of the long-term protection of the MenAfriVac vaccine

Frequent and major outbreaks of meningococcal meningitis have swept through countries in the "African meningitis belt", a region south of the Sahara that stretches from Senegal to Ethiopia, for over a century. To tackle this public health emergency, a group A polysaccharide tetanus toxoid conjugate vaccine (also called MenAfriVac) was developed against meningococcus. Using data from several studies and drawing on a statistical mathematical model, scientists from the Institut Pasteur have sought to investigate the long-term vaccine response of this vaccine.

Find out more